サンプル依頼リスト カート
  • English
  • Korean
表紙：小児神経機器の世界市場 - 2023年～2030年
市場調査レポート
商品コード
1374888

小児神経機器の世界市場 - 2023年～2030年

Global Pediatric Neurology Devices Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 194 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
小児神経機器の世界市場 - 2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 194 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

小児神経学は、新生児（新生児）、乳幼児、少年、青少年における神経障害の検出と管理を扱う専門的な治療分野です。小児神経機器は、青少年の神経学的問題に対処するために使用される機器です。小児神経機器に採用されている技術は、神経疾患を治療するために開発されたものです。

市場力学：市場促進要因と市場抑制要因

製品イントロダクションの増加

市場への小児神経デバイス導入の増加は、予測期間中の世界市場の成長を促進すると予想されます。例えば、2023年7月、Nicklaus Children's Hospitalは、新しい高密度脳波（HD EEG）システムと経頭蓋磁気刺激（TMS）装置を導入し、小児患者のケアのためにこの装置を提供する国内有数の存在として発展しました。

さらに、2022年10月、ニューロシグマ社は、小児の注意欠陥・多動性障害（ADHD）治療のためのMonarch eTNSシステムと、この開発への患者のアクセスを促進するための小児ケアコペイプログラムを導入しました。さらに、技術の進歩、認知度の向上、症例の増加なども、予測期間中の世界市場の成長に寄与すると予想されます。

高い機器コスト

神経デバイスのコストが高いことが、予測期間中の世界市場成長の妨げになると予想されます。例えば、迷走神経刺激（VNS）療法は、難治性発作の患者を治療するための確立された方法であるが、装置の初期費用は約1万米ドルであり、また、定期的な電池交換が必要であるため、全体的な費用がかさみ、世界市場の成長を鈍化させています。さらに、専門医の不足、製品開拓コストの高さなどが、予測期間における世界市場の成長を鈍らせています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • イントロダクションの増加
    • 抑制要因
      • 高いデバイスコスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • 技術動向
  • 疫学分析
  • SWOT分析
  • DMI見解

第6章 COVID-19分析

第7章 製品タイプ別

  • 神経刺激装置
  • 脳神経外科用デバイス
  • インターベンション機器
  • 髄液管理デバイス
  • その他の製品タイプ

第8章 適応症別

  • 発作
  • 脳卒中
  • 水頭症
  • 神経腫瘍学的適応
  • その他の適応症

第9章 年齢層別

  • 0～5歳
  • 5～10歳
  • 10～15歳

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター（ASC）
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • LivaNova PLC
  • Medtronic PLC, Inc.
  • Natus Medical Inc.
  • Stryker Corporation
  • B.Barun SE
  • Integra LifeSciences Corporation, Inc.
  • Boston Scientific Corporation
  • NeuroSigma, Inc.
  • Zimmer Biomet

第14章 付録

目次
Product Code: MD7189

Overview

Pediatric neurology is addressed as a specialized component of treatment that deals with the detection and management of neurological disorders in neonates (newborns), infants, juveniles, and adolescents. Pediatric neurology devices are the instruments that are utilized to address neurological issues in youngsters. The technology employed in pediatric neurology devices is developed for curing neurological conditions.

Market Dynamics: Drivers & Restraints

Increase in Product Introductions

The increase in pediatric neurological device introductions into the market is expected to boost the global market growth during the forecast period. For instance, in July 2023, Nicklaus Children's Hospital introduced a new high-density electroencephalogram (HD EEG) system and transcranial magnetic stimulation (TMS) machine, evolving as one of the foremost in the country to deliver this equipment for the care of pediatric individuals.

Moreover, in October 2022, NeuroSigma introduced the Monarch eTNS System for treating pediatric attention-deficit/hyperactivity disorder (ADHD) and the Pediatric Care Copay program to promote patient access to the development. Furthermore, growing technological advancements, growing awareness and cases among other factors are also expected to contribute to the global market growth during the forecast period.

High Device Cost

The high cost of neurology devices is expected to hamper the global market growth during the forecast period. For instance, Vagus nerve stimulation (VNS) therapy is an established method for treating patients with refractory seizures, while the initial cost of the device is about 10,000 US dollars which again requires regular battery changes adding to the overall cost, slowing the global market growth. Furthermore, the lack of professional specialists and high product development costs among other additional factors are slowing the global market growth in the forecast period.

Segment Analysis

The global pediatric neurology devices market is segmented based on product type, indication, age group, end user and region.

Nerve Simulation Product Type is Expected to Dominate Market

Owing to the increase in new product introductions into the segment the nerve simulation product type is expected to hold the majority of the global market share during the forecast period. For instance, in February 2021, the FDA awarded 510(k) authorization to electroCore to extend the authorization of gammaCore, the corporation's non-invasive vagus nerve stimulation, for the acute and preventative therapy of adolescent migraine. Moreover, in February 2023, LivaNova PLC, a top medical technology and innovation corporation, introduced SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to deliver VNS Therapy in the treatment of drug-resistant epilepsy.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increase in pediatric neurology device market developments in North America the region is expected to dominate the global market during the forecast period. For instance, in October 2022, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation, introduced the Monarch eTNS System the foremost medical device authorized by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD for pediatric patients (i.e., children ages 7-12), at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.

Also, in December 2022, Brain Scientific, a Florida-based applied science technology corporation, formed a new distribution agreement with MVAP Medical Supplies to push sales into the rapidly expanding and underserved pediatric EEG marketplace.

Further, in January 2023, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation trading external trigeminal nerve stimulation (eTNS) technology for the treatment of neurological and neuropsychiatric disorders, began a strategic digital marketing collaboration with Data360, a top provider of targeted, online marketing for the healthcare industry.

COVID-19 Impact Analysis

Various neurological manifestations have been associated with children's SARS-CoV-2 infection. It was crucial to identify and provide them with appropriate and timely treatment because they can be potentially serious and life-threatening, and some can lead to long-lasting consequences.

Different neuro-pathophysiological mechanisms were presented, but a causal relationship between SARS-CoV-2 infection and neurological manifestations stays unproven. COVID-19 affects patients with neurological diseases especially, not only by the disease itself but also by its complications and pandemic management measures, which has impacted the gbal market in a mixed way.

Market Segmentation

By Product Type

  • Neurostimulation Devices
  • Neurosurgery Devices
  • Interventional Devices
  • CSF Management Devices
  • Other Product Types

By Indication

  • Seizure
  • Stroke
  • Hydrocephalus
  • Neurooncological Indications
  • Other Indications

By Age Group

  • 0-5 Years
  • 5-10 Years
  • 10-15 Years

By End User

  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In June 2023, Biogen Inc. launched a new SPINRAZA (nusinersen) data strived to answer critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
  • In October 2022, Axoft, a neurotechnology corporation, introduced and obtained the FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.
  • In October 2022, SpineX, Inc., a clinical-stage medtech corporation reported the groundbreaking results of its first in-human study in children with cerebral palsy.
  • In January 2021, Theranica, a prescribed digital therapeutics (PDT) corporation obtained the Food and Drug Administration clearance to market its Nerivio therapeutic device for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, LivaNova PLC, Medtronic PLC, Natus Medical Inc., Stryker Corporation, B.Barun SE, Integra Lifesciences Corporation, Boston Scientific Corporation, Zimmer Biomet and NeuroSigma, Inc. among others.

Why Purchase the Report?

  • To visualize the global pediatric neurology devices market segmentation based on product type, indication, age group, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pediatric neurology devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pediatric neurology devices market report would provide approximately 69 tables, 73 figures and 194 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in Product Introductions
    • 4.1.2. Restraints
      • 4.1.2.1. High Device Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. Technology Trend
  • 5.8. Epidemiology
  • 5.9. SWOT Analysis
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Neurostimulation Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neurosurgery Devices
  • 7.4. Interventional Devices
  • 7.5. CSF Management Devices
  • 7.6. Other Product Types

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Seizure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Stroke
  • 8.4. Hydrocephalus
  • 8.5. Neurooncological Indications
  • 8.6. Other Indications

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. 0-5 Years*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. 5-10 Years
  • 9.4. 10-15 Years

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers (ASCs)
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. LivaNova PLC
  • 13.3. Medtronic PLC, Inc.
  • 13.4. Natus Medical Inc.
  • 13.5. Stryker Corporation
  • 13.6. B.Barun SE
  • 13.7. Integra LifeSciences Corporation, Inc.
  • 13.8. Boston Scientific Corporation
  • 13.9. NeuroSigma, Inc.
  • 13.10. Zimmer Biomet

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us